Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study.

NCT05388370 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05388370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05388370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
May 23, 2022
Completion date
May 23, 2028
Enrollment
124 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type 1